Topical Dutasteride Solutions for Male Pattern Hair Loss: Phase II Trial Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in PMC open access, 2025
Topical Dutasteride Solutions for Male Pattern Hair Loss: Phase II Trial Research Summary
Study conclusion
This Phase II trial tested three different concentrations of a topical dutasteride solution (0.01%, 0.02%, and 0.05%) against placebo and an active control in men with pattern hair loss. All three concentrations significantly increased hair count compared to placebo. The 0.05% concentration showed the best results. Topical application resulted in much lower systemic DHT suppression than oral dutasteride.
Strength of evidence
Who it applies to
Who was studied
Men with pattern hair loss. 135 participants. Phase II randomised controlled trial.
Who was NOT studied
Women with pattern hair loss. Men with very advanced hair loss. People outside the trial population.
What to look for when shopping
Topical dutasteride is not FDA-approved. It is an experimental treatment not yet commercially available as a standardised product. No approved topical dutasteride product exists as of 2025.
What research cannot help you decide
Whether topical dutasteride will become commercially available. Whether it is safer than oral dutasteride or oral finasteride for you. These are very early-stage findings requiring further research and a prescribing doctor.
Key findings
- All three topical dutasteride concentrations (0.01%, 0.02%, 0.05%) significantly increased hair count compared to placebo
- The 0.05% concentration produced the strongest result
- Topical application resulted in much lower suppression of DHT throughout the body compared to oral dutasteride
- No serious adverse events were reported in this trial
- This is an early-stage Phase II trial — larger Phase III trials would be needed before any regulatory approval
What this study does not show
- 1.Whether topical dutasteride is effective in a larger Phase III trial. Phase II results are preliminary.
- 2.How topical dutasteride compares to oral dutasteride or oral finasteride in efficacy.
- 3.Long-term safety and efficacy. This was a short-term dose-finding study.
- 4.Whether topical dutasteride will become commercially available or receive regulatory approval.
Limitations
- 1.Phase II trial — preliminary and designed for dose finding, not definitive efficacy assessment.
- 2.Industry-funded — introduces potential for positive result bias.
- 3.Only 135 participants — small sample for drawing firm conclusions.
- 4.No systematic review or meta-analysis of topical dutasteride exists yet.
- 5.Topical dutasteride is not approved or commercially available as of 2025.
Used in these articles
Links added as fact-checks and articles citing this study are published.